



# The Biological Influence and Clinical Relevance of Polymorphism Within the NKG2D Ligands

Jianmin Zuo\*, Fiyaz Mohammed and Paul Moss

*Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom*

NKG2D is a major regulator of the activity of cytotoxic cells and interacts with eight different ligands (NKG2DL) from two families of MIC and ULBP proteins. The selective forces that drove evolution of NKG2DL are uncertain, but are likely to have been dominated by infectious disease and cancer. Of interest, NKG2DL are some of the most polymorphic genes outside the MHC locus and the study of these is uncovering a range of novel observations regarding the structure and function of NKG2DL. Polymorphism is present within all NKG2DL members and varies markedly within different populations. Allelic variation influences functional responses through three major mechanisms. First, it may drive differential levels of protein expression, modulate subcellular trafficking, or regulate release of soluble isoforms. In addition, it may alter the affinity of interaction with NKG2D or modulate cytotoxic activity from the target cell. In particular, ligands with high affinity for NKG2D are associated with down regulation of this protein on the effector cell, effectively limiting cytotoxic activity in a negative-feedback circuit. Given these observations, it is not surprising that NKG2DL alleles are associated with relative risk for development of several clinical disorders and the critical role of the NKG2D:NKG2DL interaction is demonstrated in many murine models. Increased understanding of the biophysical and functional consequences of this polymorphism is likely to provide insights into novel immunotherapeutic approaches.

## OPEN ACCESS

### Edited by:

Nadia Guerra,  
Imperial College London,  
United Kingdom

### Reviewed by:

Bojan Polić,  
University of Rijeka, Croatia  
Jörg Wischhusen,  
Universität Würzburg, Germany  
Henry Alexander Stephens,  
Royal Free London NHS Foundation  
Trust, United Kingdom

### \*Correspondence:

Jianmin Zuo  
j.zuo@bham.ac.uk

**Keywords:** polymorphism, single nucleotide, NKG2D ligands, binding affinity, cytotoxicity, immunologic, natural killer cells

### Specialty section:

This article was submitted to NK and Innate Lymphoid Cell Biology, a section of the journal *Frontiers in Immunology*

**Received:** 28 April 2018

**Accepted:** 24 July 2018

**Published:** 16 August 2018

### Citation:

Zuo J, Mohammed F and Moss P (2018) The Biological Influence and Clinical Relevance of Polymorphism Within the NKG2D Ligands. *Front. Immunol.* 9:1820. doi: 10.3389/fimmu.2018.01820

## INTRODUCTION

NKG2D is a dominant activating receptor on cytotoxic lymphocytes, including natural killer (NK) cells,  $\gamma\delta$  T cells, NKT cells, and  $\alpha\beta$  T cell subsets (1). Engagement of NKG2D with NKG2D ligands (NKG2DLs) on target cells triggers cytotoxicity or cytokine production and plays an important role in both innate and adaptive immune responses, including control of viral infection, tumorigenesis and pathogenesis of autoimmune diseases (2–4).

A striking feature of the NKG2D:NKG2DL interaction is that only a single gene encodes NKG2D while there are eight *NKG2DL* genes within the human genome. These NKG2D ligands comprise six cytomegalovirus glycoprotein UL16 binding proteins and two major histocompatibility complex class I polypeptide-related sequences (MICA/B). In mice, NKG2D ligands comprise five RAET1 family members, three H60 proteins and MULT-1 (5–8). MICA and MICB contain  $\alpha 1$ ,  $\alpha 2$ , and  $\alpha 3$  domains together with a transmembrane domain and short cytoplasmic tail. In contrast, ULBP ectodomains comprise only the MHC-like  $\alpha 1$  and  $\alpha 2$  domain and ULBP1, ULBP2, ULBP3, and

ULBP6 are GPI-anchored receptors while ULBP4 and ULBP5 encompass a membrane anchor and cytoplasmic tail (9).

Several crystal structures of the NKG2D/NKG2DL interaction have been resolved, including NKG2D–MICA (10, 11), NKG2D–ULBP3 (12), and NKG2D–ULBP6 (13). These reveal that the symmetric NKG2D homodimer binds to a monomeric NKG2D ligand *via* a diagonal mode of engagement which is similar to TCR–pMHC interaction. In particular, the saddle-shaped NKG2D homodimer sits astride the NKG2D ligand helices with the NKG2D monomers A and B focused on the NKG2D ligand  $\alpha 2$  and  $\alpha 1$  helices, respectively (**Figure 1**) (13).

DAP10 is the binding partner for NKG2D and ligation and cross-linking of NKG2D leads to the recruitment of the p85 subunit of PI3K and Grb2–Vav1–Sos1 complex to the phosphorylated DAP10. This elicits the phosphorylation of the kinases Jak2, Stat5, Akt, MEK1/2, and Erk. This in turn induces calcium flux, actin reorganization, degranulation and, finally, cytotoxicity to target cells. PI3K inhibitors can thus completely block cytotoxic activity (14).


All *NKG2DL* genes demonstrate considerable polymorphism (15–18) and this variation is present within each of the domains and with a relatively random distribution, a feature in contrast to the focused variation that is observed with MHC class I genes (19, 20). Polymorphism is most significant within the *MICA* and *MICB* genes (17) where 62 single nucleotide polymorphisms (SNP) and 25 SNPs have been identified, respectively. In relation to the ULBP gene family, 28, 12, 10, 20, 10, and 14 SNPs have been reported within ULBP1–6 (15, 17, 21, 22). Interestingly, polymorphisms

within *MICA* and *MICB* are distributed throughout the three extracellular  $\alpha 1$ – $\alpha 3$  domains and there are no identified coding polymorphisms within residues 40–89 within the section of the  $\alpha 1$  domain that is predicted to mediate binding with NKG2D (9, 23). This profile is somewhat different to the profile of ULBP polymorphism where several variants are predicted to influence directly the site of NKG2D binding.

The frequency of individual *MICA* and *MICB* alleles varies in different populations around the world. In particular, *MICA*\*008 is the most frequent allele worldwide (9) (except in South American Indians) (24) followed by *MICA*\*002, *MICA*\*010, *MICA*\*009, and *MICA*\*004. The *MICB* gene is more homogeneous, with *MICB*\*005 being the most common allele and less representation from *MICB*\*002, *MICB*\*004, *MICB*\*008, and *MICB*\*014 (9). Population-based variations in polymorphism are also a dominant feature and with wide variation in the frequency of SNPs within *ULBP* in Euro-Caucasoid, Afro-Caribbean, and Indo-Asian individuals (15) and most variation focused within *ULBP3*, *ULBP4*, and *ULBP6* (15, 16).

## POLYMORPHISM WITHIN NKG2D LIGANDS REFLECTS THE IMPACT OF DIFFERENTIAL SELECTIVE FORCES WITHIN EVOLUTION

An important question within NKG2DL biology relates to the evolutionary pressures that have driven gene duplication and



**FIGURE 1** | Crystal structures of NKG2D–ligand complexes. **(A)** Ribbon representation of the MICA–NKG2D complex [PDB code 1HYR, Li et al. (10)]. NKG2D homodimer [NKG2D–A (brown) and NKG2D–B (green)] interacts with the  $\alpha 1$  and  $\alpha 2$  domains of monomeric MICA (orange). The clinically relevant polymorphic residue Met129 (red) in MICA is located distal to the MICA–NKG2D interface. Partially buried Met129 mediates non-polar interactions with MICA residues (ball and stick format) that protrude from the  $\alpha 2$  helix. The  $\alpha 3$  domain of MICA (residues Thr181–Ser274) has been omitted. **(B)** Ribbon representation of the ULBP6–NKG2D complex [PDB code 4S0U; Zuo et al. (13)]. NKG2D homodimer [NKG2D–A (brown) and NKG2D–B (green)] interacts with the  $\alpha 1$  and  $\alpha 2$  domains of ULBP6 (teal). The disease-associated polymorphic residue Leu106 (red) in ULBP602 is in close proximity to the ULBP6–NKG2D docking interface, inserting directly into the NKG2D hydrophobic pocket lined by several non-polar residues (ball and stick format). The figure was generated with PyMOL (Molecular Graphics System, Version 2.0 Schrödinger, LLC).

polymorphism within MIC and ULBP family members. The expression of each gene is differentially regulated within tissues and it is likely that temporal and tissue-specific regulation of NKG2DL has served to optimize control of infectious challenges while limiting the development of autoimmune complications (16). Evidence for this effect may be seen in relation to the ULBP0601 and ULBP0602 proteins, where ULBP0601 homozygosity is associated with increased cytotoxic activity in comparison to the ULBP0602 variant (13). Viral infections may have represented a particularly important selective force as viral immunoevasins generally bind only to specific ligands and no single viral immunoevasin has yet been described which can bind to all NKG2DL family members.

Assessment of NKG2DL polymorphism within different species might also provide some clues as to the pace and potential determinants of gene diversification. Meyer et al. (25) sequenced a range of *MIC* genes from non-human primates and demonstrated that these most likely derive from a single common *MICB*-like ancestor (26). Much of the polymorphism within ULBP genes appears to have arisen very early in the development of *Homo sapiens* and prior to migration out of Africa (15, 27). However, the pattern of diversity varies markedly across the globe and is likely to reflect differential selection to pathogens within different environments (9, 24). Some inferences may be drawn from the evolution of the KIR genes where, in addition to infection, a role in mediating successful pregnancy outcome also appears to be important (28).

## THE CLINICAL IMPORTANCE OF POLYMORPHISM WITHIN NKG2D LIGANDS

Polymorphisms within *NKG2DL* alleles have been identified as risk factors for a range of different clinical disorders. As discussed above, NKG2DL expression is increased by inflammatory stimuli (29) and as such the strong association of *ULBP6* SNP (rs9479482) with Alopecia Areata is compatible with its autoimmune pathogenesis (AA) (30, 31). Indeed, NKG2D<sup>+</sup> T cells have been identified as important mediators in the initiation of this disease (32). The first association of MICA polymorphism with autoimmune disease was observed by Mizuki et al. (33) in Behçet's disease and this has been followed by 12 further reports (Table 1).

Viral infection is a potent stimulus for NKG2DL expression and an early report identified that MICA polymorphism was associated with increased risk of CMV reactivation in HIV-seropositive patients (43). Strikingly, genome-wide association study analysis of 2,008 patients with pediatric Dengue shock syndrome and 2,018 controls from Vietnam demonstrated that the *MICB* polymorphism rs3134899 was one of only two associated risk alleles with a per-allele odds ratio of 1.34 (44). Moreover, a replication study in Thai patients confirmed these findings (46), which were also apparent in patients with less severe clinical phenotypes of dengue as well as an infant group (45, 46). As such, the association of *MICB* alleles with dengue is one of the most well characterized allelic associations of a non-HLA gene with any infectious disease.

Cancer may be been an important selective force in NKG2DL evolution and expression is increased markedly during cell transformation. Several reports have demonstrated an association between NKG2DL alleles and a range of different cancer subtype and it will be of interest to see if this is replicated in future studies (34–42). Tumor-specific immune responses are also central in disease control and are exemplified in stem cell transplantation (HSCT) (60) where the curative effect relies mainly on the graft versus leukemia effect. NKs contribute to alloreactive responses (61, 62) and NKG2DL polymorphism appears to play a particularly important role in this setting (63). Again, the MICA-129 Met/Val dimorphism is informative with higher relapse rates observed in association with the MICA-129Met/Met homozygous genotype (57) and increased incidence of cGVHD with MICA-129 Val/Val homozygotes (59). This has been interpreted as reflecting stronger NK and CD8<sup>+</sup> T cell activation in the presence of the MICA-129Met allele although the longer term effects may be mitigated by subsequent down regulation of NKG2D on effector cells. We also investigated the impact of ULBP in 371 SCT patient–donor pairs and related this to clinical outcome (58), observing a strong association between the ULBP0602 allele and overall survival. This effect might reflect either the direct consequence of cytotoxic activity of NK and T cells against tumor cells or a regulatory role of the NK subset on subsequent development of the alloreactive T cell response (64–67).

## THE FUNCTIONAL IMPACT OF POLYMORPHISM WITHIN NKG2D LIGAND PROTEINS

A major ambition is now to understand the biological importance of physiological variation within the NKG2DL proteins and how this information may be used both to understand established disease associations and to potentially develop novel immunotherapeutic approaches.

In this review, we address this challenge in relation to the influence of polymorphism (Figure 2) on (1) expression level of NKG2DL proteins, (2) differential affinity for NKG2D, and (3) modulation of cytotoxic activity.

### The Influence of Polymorphism on the Expression of Surface and Soluble Forms of NKG2DL

Perhaps the most immediate influence of NKG2DL polymorphism is that it may modulate the magnitude of protein expression at the cell surface. Indeed, use of a functional genomics system whereby a single copy of MICA cDNA can be stably integrated into CHO cells revealed differential transcriptional activity that varied by sixfold across four different alleles and correlated with protein expression (68). Two MICA polymorphisms associated with increased risk of HCV-related hepatocellular cancer are both located at the 5' flanking region of MICA, rs2596542 (39) being 4.7 kb and rs2596538 (40) 2.8 kb upstream of the *MICA* gene. Of interest, the rs2596538 allele is located at a binding site for transcription factor specificity protein 1 and both SNPs modulate the level of soluble MICA protein due to relative transcriptional

**TABLE 1** | The clinical relevance of polymorphism within NKG2D ligands.

	NKG2DL	Single nucleotide polymorphisms	Diseases	Reference
Malignancy association	MICA	129-Met/Val	Nasopharyngeal carcinoma	Douik et al. (34)
	MICA	MICA-5.1	Oral squamous cell carcinoma	Tamaki et al. (35, 36)
	MICA	MICA-5.1	Breast cancer	Lavado-Valenzuela et al. (37)
	MICA	213 thr and 251 gln	Cervical cancer	Jumnainsong et al. (38)
	MICA	rs2596542, rs2596538	Hepatitis C virus (HCV)-induced hepatocellular carcinoma (HCC)	Kumar et al. (39); Lo et al. (40); Goto et al. (41)
	MCIA	rs2596542G/A 129Met/Val; 251Gln/Arg 175Gly/Ser; triplet repeat	Hepatitis B virus-induced hepatocellular carcinoma	Tong et al. (42)
Virus infection	MICA	MICA-5.1	CMV reactivation in HIV-infected patients	Moenkemeyer et al. (43)
	MICB	rs3132468	Dengue shock syndrome and non-severe dengue	Khor et al. (44); Whitehorn et al. (45); Dang et al. (46)
Autoimmune diseases	MICA	129-Met/Val	Chronic Chagas heart disease	Ayo et al. (47)
	MICA	129-Met/Val	Ankylosing spondylitis	Amroun et al. (48)
	MICA	rs1051794	Rheumatoid arthritis	Kirsten et al. (49)
	MICA	129-Met/Val	Inflammatory bowel disease	Lopez-Hernandez et al. (50); Zhao et al. (51)
	MICA	129-Met/Val	Lupus erythematosus	Yoshida et al. (52)
	MICA	129-Met/Val	Type I diabetes	Raache et al. (53)
	MICA	129-Met/Val	Psoriatic disease	Pollock et al. (54)
	MICA	Triplet repeat microsatellite	Behçet disease	Mizuki et al. (33)
	MICA	MICA-A9 triplet repeat	Psoriatic arthritis	Gonzalez et al. (55)
	ULBP6	Rs1543547	Diabetic nephropathy	Mcknight et al. (56)
ULBP6	Rs9479482	Autoimmune alopecia	Petukhova et al. (30)	
HSCT	MICA	129-Met/Val	Chronic GvHD	Boukouaci et al. (57)
	ULBP6	ULBP0601/ULBP0602	HSCT overall outcome	Antoun et al. (58)
	MICA	129-Met/Val	HSCT clinical outcome	Isernhagen et al. (59)

activity at the MICA locus (39, 40). The rs1051792 SNP of the MICA gene resulting in the MICA-129Met/Val dimorphism was the first MICA polymorphism for which a functional consequence was described and the MICA-129Met variant is associated with particularly strong NKG2D engagement. The effect of this exchange is more subtle, in that the MICA-129Met variant is associated with increased transcriptional activity but protein retention within intracellular compartments (69) and higher serum MICA levels are seen in patients with hepatitis B who are homozygous for the MICA-129Val allele (42). As such, polymorphism can influence not only the magnitude of protein expression but also the pattern of expression within the cell. Our own studies have focused on polymorphism within ULBP6 (13) where stably integrated CHO cell lines with a single copy of the ULBP0601 and ULBP0602 alleles, and primary patient samples, did not reveal any difference in surface expression or shedding according to genotype.


As such, polymorphisms within NKG2DLs that act to modulate protein expression, subcellular location, and surface shedding are important regulators of differential NKG2DL activity.

## The Importance of NKG2DL Polymorphism on Binding Affinity to NKG2D

Engagement of NKG2D ligands with NKG2D is a crucial step in the activity of many cytotoxic cells. Again, study of the MICA-129 Met/Val dimorphism has been crucial in studies of how this may be influenced by allelic variation. Steinle et al. transfected a range of nine different MICA alleles into a reporter cell line and, after determining equivalent levels of cell surface expression,

then interrogated their binding to soluble NKG2D. A hierarchy of fluorescent intensity was observed, with 5 alleles demonstrating stronger binding compared to the other 4 (70). Interestingly, the presence of methionine at position 129 (Met129) was the sole determinant of strong binding. In subsequent work, Isernhagen and colleagues expressed two MICA\*0701 variants, with either methionine (the wild-type amino acid) or valine at position 129, and examined NKG2D affinity on a range of different cell types. The slope of NKG2D engagement in relation to increasing MICA expression intensity was steeper for the MICA-129Met variant, indicating higher avidity compared to the MICA-129Val variant (59). Based on the crystal structure of MICA\*01 (10), this biallelic position does not participate directly in the MICA-NKG2D interface but may indirectly modulate NKG2D binding *via* a conformational change (**Figure 1A**). The methionine side chain protrudes from the  $\beta$ -sheet base and mediates an extensive network of non-polar interactions with Gln136, Ala139, and Met140 from the N-terminal helical stretch of  $\alpha$ 2, a region that is in close proximity to the MICA-NKG2D interface (11). It is conceivable that this conformation within the MICA-Met129 variant permits optimal contacts with bound NKG2D which is presumably lost in the MICA-Val129 form and this may account for the differing ligand binding affinities associated with the MICA-129Met/Val dimorphism.

We have also examined the binding of NKG2D to recombinant forms of the two major ULBP6 alleles (ULBP0601 and ULBP0602), using surface plasmon resonance (13). Strikingly, ULBP0602 demonstrated a very high affinity for its ligand with fast binding and slow dissociation. Indeed, the measured affinity of 15.5 nM is over 10-fold higher than the equivalent binding



for ULBP0601 and substantially greater than any other ULBP family member. The structure of the NKG2D/ULBP0602 interaction revealed hydrophobic contacts at the ULBP0602/NKG2D interface sufficient to explain this difference as position Leu106 in ULBP0602, located at the NKG2D receptor ligand interface, inserts directly into the center of the hydrophobic patch B of NKG2D, forming numerous non-polar contacts with surrounding residues (Tyr152, Ile182, Met184, and Tyr199) (**Figure 1B**). In contrast, ULBP0601 has a charged and lengthy Arg at this position and its introduction within this predominantly hydrophobic environment is likely to be detrimental for NKG2D binding.

Collectively, these studies reveal that variation in the affinity of the interaction with NKG2D is likely to have acted as an important selective force in the polymorphism within NKG2D ligands.

### Polymorphism Within NKG2DL Have an Important Influence on Cytotoxic Activity of Effector Cells

The most important functional outcome of NKG2DL:NKG2D engagement is the degree of cytotoxic activity from the effector cell. A range of studies (13, 59, 68) have indicated subtle differences in NKG2DL structure can translate into significant variation in the cytotoxic capacity of effector cells. This has demonstrated clearly within the MIC-A family by increased levels of NK cell cytotoxicity and cytokine production following engagement with cells expressing the high-affinity MICA-129Met allele in comparison to those with surface expression of MICA-129Val (59). A comparable profile was observed in relation to co-stimulation of CD8<sup>+</sup>

T cells where, again, the 129Met allele provided stronger signaling to NKG2D<sup>+</sup> CD8<sup>+</sup> cells in concert with TCR engagement.

In light of these findings it might be considered that the evolution of high-affinity NKG2DL alleles would result inexorably into positive selection within a population. However, as almost always in biology, there is clearly a balance in the relation to the optimal affinity for NKG2DL:NKG2D binding. In particular, as the level of NKG2DL protein expression increases on the surface of a target cell, as might occur in the setting of viral infection or transformation, this can lead to dramatic down regulation of NKG2D expression on the effector cell in situations where the NKG2DL ligand has a high affinity for NKG2D. As such, alleles such as MICA-129Met might offer a cytotoxic advantage against targets with low levels of NKG2D expression but become counterproductive as they drive the “NKG2D exhaustion” of effector cells following high levels of expression due to cellular stress.

Striking differences are also observed in the cytotoxic capacity of NK cells taken from different donors (68). A comparison of effector cell activity from 22 healthy donors revealed marked interindividual variation in the cytotoxic ability and, surprisingly, this was correlated both positively and negatively to MICA expression level in different donors. The authors argue that individual responses are “tuned” to different “dose bandwidths” of NKG2DL expression, again challenged the simple hypothesis that higher receptor levels promote greater responsiveness.

We also observed that effector cells expressing the high-affinity ULBP6 allele, ULBP0602, elicited weaker killing from a range of effector NK and T cells compared to ULBP0601, and was correlated with less downregulation of NKG2D (13). We suggest

that this may result either from the ultra stable binding nature of the NKG2D/ULBP0602 interaction, which equates to a  $t_{1/2}$  of ~550 s at 25°C, acting to limit serial triggering of NKG2D receptors (71, 72). Alternatively, shedding of the high-affinity soluble ULBP0602 can inhibit NKG2D binding to the NKG2D ligands on the cell surface.

## Exploiting the Translational Potential of Polymorphism Within NKG2DL

The reports of polymorphism within NKG2D ligands, particularly MICA and ULBP6, and disease risk indicate that NKG2DL family members may represent an important therapeutic targets for treatment. The interaction of NKG2D and NKG2D ligands has been shown to be particularly important in the control of malignant disease. *In vivo* studies in murine models have shown that expression of NKG2D ligands on tumor cells is an important determinant of tumor control (73) and as such it is no surprise that tumor progression is associated with selection for tumor variants which are able to evade NKG2D-mediated immune recognition. In the setting of inflammatory disease, one potential strategy might be to downregulate NKG2D receptor expression on T cells and NK cells through soluble NKG2D ligands or immune suppressive cytokine (74, 75). In the setting of malignant

disease, considerably more information is required on the profile of NKG2DL expression within individual tumor and how this is related both to the profile of somatic mutations within the tumor and the tumor microenvironment. Cytokines such as TGF- $\beta$  have also been shown to regulate NKG2DL expression and represent a further influence on ligand regulation within the tumor microenvironment (76).

As such, interventions that can modulate the functional outcome of the NKG2D:NKG2D interaction may represent important and novel immunotherapeutic approaches (77). This indicates the requirement for continuing research to understand and exploit the lessons that can be derived from the extensive polymorphic variation within this remarkable ligand interaction.

## AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

## FUNDING

This study was supported by Bloodwise Project grant funding to PM (grant code 17009).

## REFERENCES

- Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. *Annu Rev Immunol* (2013) 31:413–41. doi:10.1146/annurev-immunol-032712-095951
- Ebihara T, Masuda H, Akazawa T, Shingai M, Kikuta H, Ariga T, et al. Induction of NKG2D ligands on human dendritic cells by TLR ligand stimulation and RNA virus infection. *Int Immunol* (2007) 19(10):1145–55. doi:10.1093/intimm/dxm073
- Jinushi M, Takehara T, Tatsumi T, Kanto T, Groh V, Spies T, et al. Autocrine/paracrine IL-15 that is required for type I IFN-mediated dendritic cell expression of MHC class I-related chain A and B is impaired in hepatitis C virus infection. *J Immunol* (2003) 171(10):5423–9. doi:10.4049/jimmunol.171.10.5423
- Schrama D, Terheyden P, Otto K, Kämmerer U, Bröcker E-B, Lühder F, et al. Expression of the NKG2D ligand UL16 binding protein-1 (ULBP-1) on dendritic cells. *Eur J Immunol* (2006) 36(1):65–72. doi:10.1002/eji.200535115
- Bahram S, Inoko H, Shiina T, Radosavljevic M. MIC and other NKG2D ligands: from none to too many. *Curr Opin Immunol* (2005) 17(5):505–9. doi:10.1016/j.coi.2005.07.016
- Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. *Science* (1999) 285(5428):727–9. doi:10.1126/science.285.5428.727
- Cerwenka A, Bakker ABH, McClanahan T, Wagner J, Wu J, Phillips JH, et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. *Immunity* (2000) 12(6):721–7. doi:10.1016/S1074-7613(00)80222-8
- Cosman D, Mullberg J, Sutherland C, Chin W, Armitage R, Fanslow W, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. *Immunity* (2001) 14(2):123–33. doi:10.1016/S1074-7613(01)00095-4
- Carapito R, Bahram S. Genetics, genomics, and evolutionary biology of NKG2D ligands. *Immunol Rev* (2015) 267(1):88–116. doi:10.1111/imr.12328
- Li P, Morris DL, Willcox BE, Steinle A, Spies T, Strong RK. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. *Nat Immunol* (2001) 2:443. doi:10.1038/87757
- Li P, Willie ST, Bauer S, Morris DL, Spies T, Strong RK. Crystal structure of the MHC class I homolog MIC-A, a  $\gamma\delta$  T cell ligand. *Immunity* (1999) 10(5):577–84. doi:10.1016/S1074-7613(00)80057-6
- Radaev S, Rostro B, Brooks AG, Colonna M, Sun PD. Conformational plasticity revealed by the cocrystal structure of NKG2D and its class I MHC-like ligand ULBP3. *Immunity* (2001) 15(6):1039–49. doi:10.1016/S1074-7613(01)00241-2
- Zuo J, Willcox CR, Mohammed F, Davey M, Hunter S, Khan K, et al. A disease-linked ULBP6 polymorphism inhibits NKG2D-mediated target cell killing by enhancing the stability of NKG2D ligand binding. *Sci Signal* (2017) 10(481):eaai8904. doi:10.1126/scisignal.aai8904
- Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. *Nat Immunol* (2008) 9:495. doi:10.1038/ni1581
- Antoun A, Jobson S, Cook M, O'Callaghan CA, Moss P, Briggs DC. Single nucleotide polymorphism analysis of the NKG2D ligand cluster on the long arm of chromosome 6: extensive polymorphisms and evidence of diversity between human populations. *Hum Immunol* (2010) 71(6):610–20. doi:10.1016/j.humimm.2010.02.018
- Eagle RA, Traherne JA, Hair JR, Jafferji I, Trowsdale J. ULBP6/RAET1L is an additional human NKG2D ligand. *Eur J Immunol* (2009) 39(11):3207–16. doi:10.1002/eji.200939502
- Stephens HAF. MICA and MICB genes: can the enigma of their polymorphism be resolved? *Trends Immunol* (2001) 22(7):378–85. doi:10.1016/S1471-4906(01)01960-3
- Radosavljevic M, Cuillerier B, Wilson MJ, Clement O, Wicker S, Gilfillan S, et al. A cluster of ten novel MHC class I related genes on human chromosome 6q24.2–q25.3. *Genomics* (2002) 79(1):114–23. doi:10.1006/geno.2001.6673
- Madden DR. The three-dimensional structure of peptide-MHC complexes. *Annu Rev Immunol* (1995) 13(1):587–622. doi:10.1146/annurev.iy.13.040195.003103
- Lawlor DA, Zemmour J, Ennis PD, Parham P. Evolution of class-I MHC genes and proteins: from natural selection to thymic selection. *Annu Rev Immunol* (1990) 8(1):23–63. doi:10.1146/annurev.iy.08.040190.000323
- Hubbard TJP, Aken BL, Ayling S, Ballester B, Beal K, Bragin E, et al. Ensembl 2009. *Nucleic Acids Res* (2009) 37(Database issue):D690–7. doi:10.1093/nar/gkn828
- Eagle RA, Trowsdale J. Promiscuity and the single receptor: NKG2D. *Nat Rev Immunol* (2007) 7(9):737–44. doi:10.1038/nri2144
- Strong RK. Asymmetric ligand recognition by the activating natural killer cell receptor NKG2D, a symmetric homodimer. *Mol Immunol* (2002) 38(14):1029–37. doi:10.1016/S0161-5890(02)00032-9

24. Oliveira LA, Ribas F, Bicalho MG, Tsuneto LT, Petzl-Erler ML. High frequencies of alleles MICA\*020 and MICA\*027 in Amerindians and evidence of positive selection on exon 3. *Genes Immun* (2008) 9:697. doi:10.1038/gene.2008.65
25. Meyer A, Carapito R, Ott L, Radosavljevic M, Georgel P, Adams EJ, et al. High diversity of MIC genes in non-human primates. *Immunogenetics* (2014) 66(9):581–7. doi:10.1007/s00251-014-0791-4
26. Bahram S, Dixon FJ. MIC genes: from genetics to biology. *Adv Immunol* (2001) 76:1–60. doi:10.1016/S0065-2776(01)76018-X
27. Cox ST, Arrieta-Bolanos E, Pesoa S, Vullo C, Madrigal JA, Saudemont A. RAET1/ULBP alleles and haplotypes among Kolla South American Indians. *Hum Immunol* (2013) 74(6):775–8. doi:10.1016/j.humimm.2013.01.030
28. Parham P. MHC class I molecules and KIRs in human history, health and survival. *Nat Rev Immunol* (2005) 5(3):201–14. doi:10.1038/nri1570
29. Caillat-Zucman S. How NKG2D ligands trigger autoimmunity? *Hum Immunol* (2006) 67(3):204–7. doi:10.1016/j.humimm.2006.02.013
30. Petukhova L, Duvic M, Hordinsky M, Norris D, Price V, Shimomura Y, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. *Nature* (2010) 466(7302):113–7. doi:10.1038/nature09114
31. Jagielska D, Redler S, Brockschmidt FF, Herold C, Pasternack SM, Garcia Bartels N, et al. Follow-up study of the first genome-wide association scan in alopecia areata: IL13 and KIAA0350 as susceptibility loci supported with genome-wide significance. *J Invest Dermatol* (2012) 132(9):2192–7. doi:10.1038/jid.2012.129
32. Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. *Nat Med* (2014) 20(9):1043–9. doi:10.1038/nm.3645
33. Mizuki N, Ota M, Kimura M, Ohno S, Ando H, Katsuyama Y, et al. Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Behcet disease. *Proc Natl Acad Sci U S A* (1997) 94(4):1298–303. doi:10.1073/pnas.94.4.1298
34. Douik H, Chaaben AB, Romdhane NA, Ben Romdhane H, Mamoghli T, Fortier C, et al. Association of MICA-129 polymorphism with nasopharyngeal cancer risk in a Tunisian population. *Hum Immunol* (2009) 70(1):45–8. doi:10.1016/j.humimm.2008.10.008
35. Tamaki S, Sanefuzi N, Ohgi K, Imai Y, Kawakami M, Yamamoto K, et al. An association between the MICA-A5.1 allele and an increased susceptibility to oral squamous cell carcinoma in Japanese patients. *J Oral Pathol Med* (2007) 36(6):351–6. doi:10.1111/j.1600-0714.2007.00539.x
36. Tamaki S, Kawakami M, Yamanaka Y, Shimomura H, Imai Y, Ishida J-I, et al. Relationship between soluble MICA and the MICA A5.1 homozygous genotype in patients with oral squamous cell carcinoma. *Clin Immunol* (2009) 130(3):331–7. doi:10.1016/j.clim.2008.09.004
37. Lavado-Valenzuela R, Benavides M, Carabantes F, Alonso A, Caballero A. MHC class I chain-related gene A transmembrane polymorphism in Spanish women with breast cancer. *Tissue Antigens* (2009) 74(1):46–9. doi:10.1111/j.1399-0039.2009.01254.x
38. Jumnainsong A, Romphruk AV, Jearanaikoon P, Klumkrathok K, Romphruk A, Luanrattanakorn S, et al. Association of polymorphic extracellular domains of MICA with cervical cancer in northeastern Thai population. *Tissue Antigens* (2007) 69(4):326–33. doi:10.1111/j.1399-0039.2006.00754.x
39. Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, Hosono N, et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. *Nat Genet* (2011) 43:455. doi:10.1038/ng.809
40. Lo PHY, Urabe Y, Kumar V, Tanikawa C, Koike K, Kato N, et al. Identification of a functional variant in the MICA promoter which regulates MICA expression and increases HCV-related hepatocellular carcinoma risk. *PLoS One* (2013) 8(4):e61279. doi:10.1371/journal.pone.0061279
41. Goto K, Kato N. MICA SNPs and the NKG2D system in virus-induced HCC. *J Gastroenterol* (2015) 50(3):261–72. doi:10.1007/s00535-014-1000-9
42. Tong HV, Toan NL, Song LH, Bock CT, Kremsner PG, Velavan TP. Hepatitis B virus-induced hepatocellular carcinoma: functional roles of MICA variants. *J Viral Hepat* (2013) 20(10):687–98. doi:10.1111/jvh.12089
43. Moenkemeyer M, Heiken H, Schmidt RE, Witte T. Higher risk of cytomegalovirus reactivation in human immunodeficiency virus-1-infected patients homozygous for MICA5.1. *Hum Immunol* (2009) 70(3):175–8. doi:10.1016/j.humimm.2009.01.005
44. Khor CC, Bich CTN, Pang J, Davila S, Long HT, Ong RTH, et al. Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1. *Nat Genet* (2011) 43(11):1139–41. doi:10.1038/ng.960
45. Whitehorn J, Chau TNB, Nguyet NM, Kien DTH, Quyen NTH, Trung DT, et al. Genetic variants of MICB and PLCE1 and associations with non-severe dengue. *PLoS One* (2013) 8(3):e59067. doi:10.1371/journal.pone.0059067
46. Dang TN, Naka I, Sa-Ngasang A, Anantapreecha S, Chanama S, Wichukchinda N, et al. A replication study confirms the association of GWAS-identified SNPs at MICB and PLCE1 in Thai patients with dengue shock syndrome. *BMC Med Genet* (2014) 15:58. doi:10.1186/1471-2350-15-58
47. Ayo CM, de Oliveira AP, Camargo AV, Brandao de Mattos CC, Bestetti RB, de Mattos LC. Association of the functional MICA-129 polymorphism with the severity of chronic Chagas heart disease. *Clin Infect Dis* (2015) 61(8):1310–3. doi:10.1093/cid/civ540
48. Amroun H, Djoudi H, Busson M, Allat R, El Sherbini SM, Sloma I, et al. Early-onset ankylosing spondylitis is associated with a functional MICA polymorphism. *Hum Immunol* (2005) 66(10):1057–61. doi:10.1016/j.humimm.2005.09.004
49. Kirsten H, Petit-Teixeira E, Scholz M, Hasenclever D, Hantmann H, Heider D, et al. Association of MICA with rheumatoid arthritis independent of known HLA-DRB1 risk alleles in a family-based and a case control study. *Arthritis Res Ther* (2009) 11(3):R60. doi:10.1186/ar2683
50. Lopez-Hernandez R, Valdes M, Lucas D, Campillo JA, Martinez-Garcia P, Salama H, et al. Association analysis of MICA gene polymorphism and MICA-129 dimorphism with inflammatory bowel disease susceptibility in a Spanish population. *Hum Immunol* (2010) 71(5):512–4. doi:10.1016/j.humimm.2010.02.003
51. Zhao J, Jiang Y, Lei Y, Zou K, Wang C, Huang S, et al. Functional MICA-129 polymorphism and serum levels of soluble MICA are correlated with ulcerative colitis in Chinese patients. *J Gastroenterol Hepatol* (2011) 26(3):593–8. doi:10.1111/j.1440-1746.2010.06524.x
52. Yoshida K, Komai K, Shiozawa K, Mashida A, Horiuchi T, Tanaka Y, et al. Role of the MICA polymorphism in systemic lupus erythematosus. *Arthritis Rheum* (2011) 63(10):3058–66. doi:10.1002/art.30501
53. Raache R, Belanteur K, Amroun H, Benyahia A, Heniche A, Azzouz M, et al. Association of major histocompatibility complex class 1 chain-related gene A dimorphism with type 1 diabetes and latent autoimmune diabetes in adults in the Algerian population. *Clin Vaccine Immunol* (2012) 19(4):557–61. doi:10.1128/01.05473-11
54. Pollock RA, Chandran V, Pellett FJ, Thavaneswaran A, Eder L, Barrett J, et al. The functional MICA-129 polymorphism is associated with skin but not joint manifestations of psoriatic disease independently of HLA-B and HLA-C. *Tissue Antigens* (2013) 82(1):43–7. doi:10.1111/tan.12126
55. Gonzalez S, Martinez-Borra J, Torre-Alonso JC, Gonzalez-Roces S, Sanchez Del Rio J, Rodriguez Pérez A, et al. The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw\*0602 in psoriasis. *Arthritis Rheum* (1999) 42(5):1010–6. doi:10.1002/1529-0131(199905)42:5<1010::AID-ANR21>3.0.CO;2-H
56. McKnight AJ, Currie D, Patterson CC, Maxwell AP, Fogarty DG. Targeted genome-wide investigation identifies novel SNPs associated with diabetic nephropathy. *HUGO J* (2009) 3(1):77–82. doi:10.1007/s11568-010-9133-2
57. Boukouaci W, Busson M, Peffault de Latour RG, Rocha V, Suberbielle C, Bengoufa D, et al. MICA-129 genotype, soluble MICA, and anti-MICA antibodies as biomarkers of chronic graft-versus-host disease. *Blood* (2009) 114(25):5216–24. doi:10.1182/blood-2009-04-217430
58. Antoun A, Vekaria D, Salama RA, Pratt G, Jobson S, Cook M, et al. The genotype of RAET1L (ULBP6), a ligand for human NKG2D (KLRK1), markedly influences the clinical outcome of allogeneic stem cell transplantation. *Br J Haematol* (2012) 159(5):589–98. doi:10.1111/bjh.12072
59. Isernhagen A, Malzahn DR, Viktorova E, Elsner L, Monecke S, von Bonin F, et al. The MICA-129 dimorphism affects NKG2D signaling and outcome of hematopoietic stem cell transplantation. *EMBO Mol Med* (2015) 7(11):1480–502. doi:10.15252/emmm.201505246
60. Copelan EA. Hematopoietic stem-cell transplantation. *N Engl J Med* (2006) 354(17):1813–26. doi:10.1056/NEJMra052638
61. Chan YLT, Zuo J, Inman C, Croft W, Begum J, Croudace J, et al. NK cells produce high levels of IL-10 early after allogeneic stem cell transplantation and suppress development of acute GVHD. *Eur J Immunol* (2017) 48(2):316–29. doi:10.1002/eji.201747134
62. Maggs L, Kinsella F, Chan YLT, Eldershaw S, Murray D, Nunnick J, et al. The number of CD56dim NK cells in the graft has a major impact on risk of disease

- relapse following allo-HSCT. *Blood Adv* (2017) 1(19):1589–97. doi:10.1182/bloodadvances.2017008631
63. Kitcharoen K, Witt CS, Romphruk AV, Christiansen FT, Leelayuwat C. MICA, MICB, and MHC beta block matching in bone marrow transplantation: relevance to transplantation outcome. *Hum Immunol* (2006) 67(3):238–46. doi:10.1016/j.humimm.2006.02.012
  64. Andrews DM, Estcourt MJ, Andoniou CE, Wikstrom ME, Khong A, Voigt V, et al. Innate immunity defines the capacity of antiviral T cells to limit persistent infection. *J Exp Med* (2010) 207(6):1333–43. doi:10.1084/jem.20091193
  65. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKP30 receptor by activated NK cells. *J Exp Med* (2002) 195(3):343–51. doi:10.1084/jem.20011149
  66. Ghadially H, Ohana M, Elboim M, Gazit R, Gur C, Nagler A, et al. NK cell receptor NKP46 regulates graft-versus-host disease. *Cell Rep* (2014) 7(6):1809–14. doi:10.1016/j.celrep.2014.05.011
  67. Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. *J Exp Med* (2002) 195(3):335–41. doi:10.1084/jem.20010934
  68. Shafi S, Vantourout P, Wallace G, Antoun A, Vaughan R, Stanford M, et al. An NKG2D-mediated human lymphoid stress surveillance response with high interindividual variation. *Sci Transl Med* (2011) 3(113):113ra124. doi:10.1126/scitranslmed.3002922
  69. Isernhagen A, Schilling D, Monecke S, Shah P, Elsner L, Walter L, et al. The MICA-129Met/Val dimorphism affects plasma membrane expression and shedding of the NKG2D ligand MICA. *Immunogenetics* (2016) 68(2):109–23. doi:10.1007/s00251-015-0884-8
  70. Steinle A, Li P, Morris DL, Groh V, Lanier LL, Strong RK, et al. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. *Immunogenetics* (2001) 53(4):279–87. doi:10.1007/s002510100325
  71. Valitutti S, Muller S, Salio M, Lanzavecchia A. Degradation of T cell receptor (TCR)-CD3-zeta complexes after antigenic stimulation. *J Exp Med* (1997) 185(10):1859–64. doi:10.1084/jem.185.10.1859
  72. van der Merwe PA, Dushek O. Mechanisms for T cell receptor triggering. *Nat Rev Immunol* (2011) 11(1):47–55. doi:10.1038/nri2887
  73. Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. *Proc Natl Acad Sci U S A* (2001) 98(20):11521–6. doi:10.1073/pnas.201238598
  74. Parry HM, Stevens T, Oldreive C, Zadran B, McSkeane T, Rudzki Z, et al. NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma. *Oncotarget* (2016) 7(42):68513–26. doi:10.18632/oncotarget.12097
  75. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. *Nature* (2002) 419(6908):734–8. doi:10.1038/nature01112
  76. Chen XH, Lu L, Ke HP, Liu ZC, Wang HF, Wei W, et al. The TGF- $\beta$ -induced up-regulation of NKG2DLs requires AKT/GSK-3 $\beta$ -mediated stabilization of SP1. *J Cell Mol Med* (2017) 21(5):860–70. doi:10.1111/jcmm.13025
  77. Karimi MA, Bryson JL, Richman LP, Fesnak AD, Lechner TM, Satake A, et al. NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT. *Blood* (2015) 125(23):3655–63. doi:10.1182/blood-2015-02-629006

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Zuo, Mohammed and Moss. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.